Chosen Diagnostics

Chosen Diagnostics is an award-winning, female-owned small business that combines scientific expertise with leading-edge technologies in biomarker development. Since 2017, the company has focused on delivering better outcomes for the most urgent and complex challenges in science and technology. It is a spin-off company from LSU Health Sciences Center and housed at the New Orleans BioInnovation Center, a non-profit life sciences start-up incubator. In 2021, the company received a $2.1 million grant from the National Institute of Health to complete their NECDetect prototype which identifies necrotizing enterocolitis (NEC) in preterm infants, a disease that typically results in a 50% mortality rate. ‍